From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Shionogi & Co., Ltd.
Public (K.K)
Traded asTYO: 4507
Nikkei 225 Component
IndustryBiotechnology & Pharmaceuticals
FoundedOsaka, Japan (March 17, 1878 (1878-03-17))
FounderGisaburo Shiono, Sr.
Headquarters1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan
Key people
RevenueIncrease $ 3.009 billion USD (FY 2012)
(¥ 282.904 billion JPY) (FY 2012)
Increase $709.79 million USD (FY 2012)
(¥ 66.728 billion JPY) (FY 2012)
Number of employees
Consolidated : 6,082
WebsiteOfficial website
Footnotes / references

Shionogi & Company, Limited (塩野義製薬株式会社, Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses Shionogi ("シオノギ").

Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.

In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.

Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[3]

The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[4]



  • Shionogi has a close relationship with Fuji Television Network, Inc., because Shionogi is the sponsor of "Music Fair" (as of 2020, aired on 17 TV stations including TV Oita System Co.) started in 1964.
  • Shionogi was a main sponsor of Team Lotus in the team's final years between 1991 to 1994.[6]


  1. ^ "Shionogi Company Profile". Retrieved 18 March 2014.
  2. ^ "Shionogi Annual Report 2013" (PDF). Retrieved 18 March 2014.
  3. ^ "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". Retrieved 18 March 2014.
  4. ^ "Components:Nikkei Stock Average". Nikkei Inc. Retrieved 11 March 2014.
  5. ^ "Duchesnay acquires Osphena from Shionogi Inc" (Press release). Duchesnay. 10 March 2017. Archived from the original on 24 October 2019. Retrieved 23 October 2019.
  6. ^ Perry, Alan. "Sponsor Company Profiles". Retrieved 25 April 2012.

External links[edit]